Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation

Cell Death and Disease

Volumn 3, Issue 11, 2012, Pages

  Westerberg, C Möller ^a,b   Hagglund H ^b   Nilsson, G ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Bim; Mast cells; Mastocytosis; MG132; Velcade

Indexed keywords

BIM PROTEIN; CASPASE 3; CASPASE 3 INHIBITOR; GLYCINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; VALINE;

ARTICLE; CELL LINE; CONTROLLED STUDY; DIAGNOSTIC KIT; HUMAN; HUMAN CELL; MAST CELL; MASTOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UMBILICAL CORD; UPREGULATION; WILD TYPE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CELL LINE; DOWN-REGULATION; HUMANS; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MEMBRANE PROTEINS; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; UP-REGULATION;

EID: 84870567923     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.157     Document Type: Article

References (37)

1. Valent P, Akin C, Sperr WR, Mayerhofer M, Fodinger M, Fritsche-Polanz R et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005; 46: 35-48.
2. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
3. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L; REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138: 12-30.
4. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736-1744.
5. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560-10564.
6. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741-1744.
7. Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, Casteran N et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003; 22: 660-664.
8. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-1703.
9. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473-481.
10. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286-291.
11. Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P et al. EXEL- 0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007; 109: 315-322.
12. Kosmider O, Denis N, Dubreuil P, Moreau-Gachelin F. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene 2007; 26: 3904-3908.
13. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752-759.
14. Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 2009; 114: 5342-5351.
15. Verstovsek S, Akin C, Manshouri T, Quintas-Cardama A, Huynh L, Manley P et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 2006; 30: 1365-1370.
16. Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA III, Sundaramoorthi R et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood 2005; 106: 227-234.
17. Gabillot-Carre M, Lepelletier Y, Humbert M, de Sepuvelda P, Hamouda NB, Zappulla JP et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 2006; 108: 1065-1072.
18. Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005; 105: 2324-2331.
19. Moller C, Alfredsson J, Engstrom M, Wootz H, Xiang Z, Lennartsson J et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 2005; 106: 1330-1336.
20. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3- only protein, Bim. J Biol Chem 2003; 278: 18811-18816.
21. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22: 6785-6793.
22. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988; 12: 345-355.
23. Sundstrom M, Vliagoftis H, Karlberg P, Butterfield JH, Nilsson K, Metcalfe DD et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 2003; 108: 89-97.
24. Ekoff M, Kaufmann T, Engstrom M, Motoyama N, Villunger A, Jonsson JI et al. The BH3- only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 2007; 110: 3209-3217.
25. Alfredsson J, Puthalakath H, Martin H, Strasser A, Nilsson G. Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl- XL upon IgE-receptor activation. Cell Death Differ 2005; 12: 136-144.
26. Ko JK, Choi CH, Kim YK, Kwon CH. The proteasome inhibitor MG-132 induces AIF nuclear translocation through down-regulation of ERK and Akt/mTOR pathway. Neurochem Res 2011; 36: 722-731.
27. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev 2005; 5: 189-200.
28. Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010; 17: 125-132.
29. Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686-692.
30. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
31. Miasari M, Puthalakath H, Silke J. Ubiquitylation and cancer development. Curr Cancer Drug Targets 2008; 8: 118-123.
32. Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NFkappaB- dependent process. Oncogene 2003; 22: 7108-7122.
33. O'Reilly LA, Cullen L, Visvader J, Lindeman GJ, Print C, Bath ML et al. The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am J Pathol 2000; 157: 449-461.
34. Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K et al. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 2004; 24: 6172-6183.
35. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 2005; 65: 9436-9444.
36. Gulliksson M, Palmberg L, Nilsson G, Ahlstedt S, Kumlin M. Release of prostaglandin D2 and leukotriene C4 in response to hyperosmolar stimulation of mast cells. Allergy 2006; 61: 1473-1479.
37. Nilsson G, Blom T, Harvima I, Kusche-Gullberg M, Nilsson K, Hellman L. Stem cell factordependent human cord blood derived mast cells express alpha- and beta-tryptase, heparin and chondroitin sulphate. Immunology 1996; 88: 308-314.